Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, Yoshida T, Ishii H, Furuse J, Sugiyama E, Kim SR, Kikura-Hanajiri R, Hasegawa R, Saito Y, Ozawa S, Kaniwa N, Sawada J. Yonemori K, et al. Among authors: sawada j. Clin Cancer Res. 2005 Apr 1;11(7):2620-4. doi: 10.1158/1078-0432.CCR-04-1497. Clin Cancer Res. 2005. PMID: 15814642 Clinical Trial.
Identification of a predictive biomarker for hematologic toxicities of gemcitabine.
Matsubara J, Ono M, Negishi A, Ueno H, Okusaka T, Furuse J, Furuta K, Sugiyama E, Saito Y, Kaniwa N, Sawada J, Honda K, Sakuma T, Chiba T, Saijo N, Hirohashi S, Yamada T. Matsubara J, et al. Among authors: sawada j. J Clin Oncol. 2009 May 1;27(13):2261-8. doi: 10.1200/JCO.2008.19.9745. Epub 2009 Mar 16. J Clin Oncol. 2009. PMID: 19289617
Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E, Kaniwa N, Kim SR, Hasegawa R, Saito Y, Ueno H, Okusaka T, Ikeda M, Morizane C, Kondo S, Yamamoto N, Tamura T, Furuse J, Ishii H, Yoshida T, Saijo N, Sawada J. Sugiyama E, et al. Among authors: sawada j. Clin Pharmacokinet. 2010 Aug;49(8):549-58. doi: 10.2165/11532970-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20608756
Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1).
Kim SR, Saito Y, Maekawa K, Sugiyama E, Kaniwa N, Ueno H, Okusaka T, Morizane C, Yamamoto N, Ikeda M, Yoshida T, Minami H, Furuse J, Ishii H, Saijo N, Kamatani N, Ozawa S, Sawada J. Kim SR, et al. Among authors: sawada j. Drug Metab Pharmacokinet. 2006 Jun;21(3):248-56. doi: 10.2133/dmpk.21.248. Drug Metab Pharmacokinet. 2006. PMID: 16858130 Free article.
Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer.
Nakajima Y, Yoshitani T, Fukushima-Uesaka H, Saito Y, Kaniwa N, Kurose K, Ozawa S, Aoyagi N, Kamatani N, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Yoshida T, Minami H, Saijo N, Katori N, Sawada J. Nakajima Y, et al. Among authors: sawada j. Clin Pharmacol Ther. 2006 Aug;80(2):179-91. doi: 10.1016/j.clpt.2006.04.012. Epub 2006 Jul 3. Clin Pharmacol Ther. 2006. PMID: 16890579
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
Sai K, Saito Y, Fukushima-Uesaka H, Kurose K, Kaniwa N, Kamatani N, Shirao K, Yamamoto N, Hamaguchi T, Kunitoh H, Ohe Y, Tamura T, Yamada Y, Minami H, Ohtsu A, Yoshida T, Saijo N, Sawada J. Sai K, et al. Among authors: sawada j. Cancer Chemother Pharmacol. 2008 Aug;62(3):529-37. doi: 10.1007/s00280-007-0634-1. Epub 2007 Nov 8. Cancer Chemother Pharmacol. 2008. PMID: 17992531
451 results